8 completed, 2 terminated, 1 recruiting, 1 unknown. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Nausea and Vomiting: new trials by email Literature Review of Nausea and Vomiting trials Research Report on Nausea and Vomiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation Glycopyrrolate, Anisodamine - Nausea and Vomiting | Phase 1 / Phase 2 | Completed | Jie Chen | 130 | 2023-10-01 | 2024-09-05 |
| Effect of Inhaled Aromatherapy on Chemo-Induced Nausea Vomiting (NCVI): CINVAROM (Chemotherapy Induced Nausea Vomiting and AROMatherapy) Essential oils - Nausea and Vomiting, Aromatherapy | Phase 2 | Completed | Centre Francois Baclesse | 96 | 2020-12-14 | 2026-08-17 |
| Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery Ropivacaine - Nausea and Vomiting, Laparoscopic Bariatric Surgery | Phase 2 | Unknown | Tianjin Medical University General Hospital | 120 | 2020-09-25 | 2021-08-23 |
| Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer palonosetron hydrochloride, placebo - Anal Cancer, Carcinoma of the Appendix | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 7 | 2009-09-01 | 2017-11-24 |
| Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride - Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Terminated | University of Washington | 6 | 2009-02-01 | 2017-05-18 |
| Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX aprepitant, dexamethasone, fluorouracil - Colorectal Cancer, Nausea and Vomiting | Phase 2 | Completed | OHSU Knight Cancer Institute | 54 | 2006-06-01 | 2017-06-12 |
| Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Prochlorperazine, Ondansetron - Nausea and Vomiting | Phase 2 | Completed | Emory University | 64 | 2005-03-01 | 2014-05-19 |
| Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy Aprepitant, Ondansetron, GW679769 - Nausea and Vomiting, Chemotherapy-Induced | Phase 2 | Completed | GlaxoSmithKline | 492 | 2005-02-01 | 2010-05-10 |
| UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer ginger extract, placebo - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 180 | 2003-05-01 | 2016-10-21 |
| Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy dolasetron mesylate, granisetron hydrochloride, ondansetron - Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 2 | Completed | Gary Morrow | 700 | 1999-10-01 | 2015-10-15 |
| Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery octreotide acetate - Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction | Phase 2 | Completed | Northwestern University | 1999-10-01 | 2012-06-06 |
Nausea (12) · Vomiting (12) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Rectal Neoplasms (3) · Bile Duct Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Constipation (1) · Gallbladder Neoplasms (1) · Gastrointestinal Stromal Tumors (1)
Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Signs and Symptoms, Digestive (12) · Neoplasms (4) · Neoplasms by Site (4) · Carcinoma (3) · Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3)
Ondansetron (4) · Dexamethasone (3) · Palonosetron (3) · Aprepitant (2) · fosaprepitant (2) · Calcium Dobesilate (1) · Cisplatin (1) · Fluorouracil (1) · Glycopyrrolate (1) · Granisetron (1) · Irinotecan (1) · L 758298 (1) · Leucovorin (1) · Octreotide (1) · Oils, Volatile (1)
Alliance for Clinical Trials in Oncology (1) · Centre Francois Baclesse (1) · Emory University (1) · Gary Morrow (1) · GlaxoSmithKline (1) · Jie Chen (1) · Montefiore Medical Center (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Tianjin Medical University General Hospital (1) · University of Michigan Rogel Cancer Center (1) · University of Washington (1)
United States (8) · China (2) · Argentina (1) · Austria (1) · Belgium (1) · Chile (1) · Croatia (1) · Czechia (1) · France (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Mexico (1) · Netherlands (1) · Pakistan (1)
Benjamin W Friedman, MD MS (1) · Daniel T Wu, MD (1) · Gary R. Morrow, PhD, MS (1) · Guangyou Duan, doctor (1) · Guolin Wang, MD (1) · J. Cameron Muir, MD (1) · John Patka, PharmD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Keith Eaton (1) · Michele Yvette Halyard, MD (1) · Suzanna Zick, MPH, ND (1)
P30CA046592 (1)